EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
EPRS was delisted on the 3rd of August, 2016.
32 hedge funds and large institutions have $2.6M invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 14 closing their positions.
14% less funds holding
Funds holding: 37 → 32 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
93% less capital invested
Capital invested by funds: $35.1M → $2.6M (-$32.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$190K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$63.5K |
| 3 |
Goldman Sachs
New York
|
+$26.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$14.1K |
| 5 |
Walleye Trading
New York
|
+$2.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$7.03M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.7M |
| 3 |
BC
Broadfin Capital
New York
|
-$2.9M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.41M |
| 5 |
B
Bailard
Foster City,
California
|
-$1.63M |
EPRS Hedge Fund Activity: Q2 2016 in Review
32 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q2 2016, worth a combined $2.6M — down 93% from $35.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of EPRS and 9 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Virtu KCG Holdings, adding an estimated $190K. The largest seller was Jennison Associates, exiting entirely with an estimated $7.03M sold.
- 32 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q2 2016, down from 37 in Q1 2016.
- Funds reported $2.6M of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q2 2016, down 93% quarter-over-quarter.
- 9 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q2 2016 and 14 closed out, a net change of -5 holders.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM buyer in Q2 2016 was Virtu KCG Holdings, an estimated $190K added.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q2 2016 was Jennison Associates, an estimated $7.03M sold.
Based on aggregated 13F filings for Q2 2016.